Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance

Leng-Fang Wang, Chun Yuan Ting, Cheng Kai Lo, Jin Shan Su, Lyn A. Mickley, Antonio T. Fojo, Jacqueline Whang-Peng, Jaulang Hwang

研究成果: 雜誌貢獻文章同行評審

51 引文 斯高帕斯(Scopus)


A camptothecin-resistant cell line that exhibits more than 600-fold resistance to camptothecin, designated CPT(R)-2000, was established from mutagen-treated A2780 ovarian cancer cells. CPT(R)-2000 cells also exhibit 3- fold resistance to a DNA minor groove-binding ligand Ho33342, a different class of mammalian DNA topoisomerase I inhibitors. However, CPT(R)-2000 cells exhibit no cross-resistance toward drugs such as Adriamycin, amsacrine, vinblastine, and 4'-dimethyl-epipodophyllotoxin. The mRNA, protein levels, and enzyme-specific activity of DNA topoisomerase I are relatively the same in parental and CPT(R)-2000 cells. However, unlike the DNA topoisomerase I activity of parental cells, which can be inhibited by camptothecin, that of CPT(R)-2000 cells cannot. In addition, parental cells after camptothecin treatment results in a decrease in the level of DNA topoisomerase I, whereas CPT(R)-2000 cells are insensitive to camptothecin treatment. These results suggested that the mechanism of camptothecin resistance is most likely due to a DNA topoisomerase I structural mutation. This notion is supported by DNA sequencing results confirming that DNA topoisomerase I of CPT(R)-2000 is mutated at amino acid residues Gly 717 to Val and Thr 729 to Ile. We also used the yeast system to examine the mutation(s) responsible for camptothecin resistance. Our results show that each single amino acid change results in partial resistance, and the double mutation gives a synergetic effect on camptothecin resistance. Because both mutation sites are near the catalytic active center, this observation raises the possibility that camptothecin may act at the vicinity of the catalytic active site of the enzyme-camptothecin- DNA complex.
頁(從 - 到)1516-1522
期刊Cancer Research
出版狀態已發佈 - 1997

ASJC Scopus subject areas

  • 癌症研究
  • 腫瘤科


深入研究「Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance」主題。共同形成了獨特的指紋。